Discover how sotagliflozin could revolutionize the management of type II diabetes in patients with chronic kidney disease, as we delve into the latest findings from a comprehensive meta-analysis of randomized controlled trials.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials.
Dos Santos Borges et al., J Nephrol 2023
DOI: 10.1007/s40620-023-01818-2
Summary of Sotagliflozin Efficacy and Safety in T2DM Patients with CKD
Background: The impact of Sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2, on patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) was uncertain.
Methods: A meta-analysis of randomized controlled trials was conducted, comparing Sotagliflozin to placebo in T2DM patients with CKD. Data from three studies involving 11,648 patients over approximately 16 months were analyzed.
Results: Sotagliflozin led to a significant reduction in HbA1C (-0.33%) and weight (-1.01 kg). No significant differences were found in all-cause mortality or major adverse cardiovascular events. However, Sotagliflozin was associated with a reduction in estimated glomerular filtration rate (-0.95), and increased risks of genital mycotic infections (RR 2.73), diarrhea (RR 1.42), and volume depletion (RR 1.31).
Conclusion: Sotagliflozin is effective for glycemic control and weight loss in T2DM patients with CKD. While it does not increase mortality or cardiovascular events, it does pose higher risks for certain adverse effects such as reduced kidney function and infections.
Significance: This analysis provides important safety and efficacy information for clinicians considering Sotagliflozin for T2DM patients with CKD, highlighting both its benefits and potential risks.